Compound heterozygous UGT1A1*28 and UGT1A1*6 or single homozygous UGT1A1*28 are major genotypes associated with Gilbert ? s syndrome in Chinese Han people

被引:6
|
作者
Zhang, Meng [1 ]
Wang, Hongwu [1 ]
Huang, Yuancheng [1 ,2 ]
Xu, Xin [1 ]
Liu, Wei [1 ]
Ning, Qin [1 ]
Chen, Tao [1 ]
Qi, Junying [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept & Inst Infect Dis, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Phys Examinat Ctr, Wuhan, Hubei, Peoples R China
关键词
Hyperbilirubinemia; Genotype; Chinese people; CRIGLER-NAJJAR-SYNDROME; SERUM BILIRUBIN CONCENTRATIONS; UGT1A1; GENE-MUTATIONS; INHERITED DISORDERS; NEONATAL HYPERBILIRUBINEMIA; UDP-GLUCURONOSYLTRANSFERASE-1; VARIANTS; PROMOTER; POLYMORPHISM; METABOLISM;
D O I
10.1016/j.gene.2021.145526
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gilbert?s syndrome (GS) is a mild condition characterized by periods of hyperbilirubinemia, which results in variations in the UDP-glucuronosyltransferase 1 (UGT1A1) gene. Variant genotypes of UGT1A1 vary in different populations in the world. The present study aimed to determine the genotype of the UGT1A1 promoter and exon that are related to the serum total bilirubin (STB) level in the Chinese Han population. A total of 120 individuals diagnosed with GS (GS group) and 120 healthy individuals (non-GS group) were enrolled. Routine blood, liver function tests, and antibodies associated with autoimmune liver diseases were assessed. Blood samples were collected for DNA purification. Sequencing of the UGT1A1 promoter and exons was conducted for post segment amplification by PCR. Compound heterozygous UGT1A1*28 and UGT1A1*6 (25/120, 20.83%), single homozygous UGT1A1*28 (24/120, 20.00%) and single heterozygous UGT1A1*6 (18/120, 15.00%) were the most frequent genotypes in the GS group. However, single heterozygous UGT1A1*6 (30/120, 25.00%) and single heterozygous UGT1A1*28 (19/120, 15.83%) were the most frequent genotypes in the non-GS group. Further, the frequencies of single homozygous UGT1A1*28, compound heterozygous UGT1A1*28 and UGT1A1*6, and compound heterozygous UGT1A1*28, UGT1A1*6 and UGT1A1*27 were significantly higher in the GS group than those in the non-GS group. The STB levels of GS patients with the homozygous UGT1A1*28 genotype were remarkably higher than those of patients with other genotypes. Homozygous UGT1A1*28 and heterozygous UGT1A1*6 variants were associated with the highest and lowest risks of hyperbilirubinemia, respectively. Our study revealed that compound heterozygous UGT1A1*28 and UGT1A1*6, or single homozygous UGT1A1*28 are major genotypes associated with GS in Chinese Han people. These findings might facilitate the precise genomic diagnosis of Gilbert?s syndrome.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] A population study on the UGT1A1*28 variant associated to irinotecan tolerance
    Roman, Ruth
    Colomer, Anna
    Erill, Nadina
    Verdú, Montse
    Ibañez, Rosa
    Cardo, Carles Cordon
    Puig, Xavier
    MODERN PATHOLOGY, 2006, 19 : 142 - 142
  • [42] UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone
    Stormo, Camilla
    Bogsrud, Martin P.
    Hermann, Monica
    Asberg, Anders
    Piehler, Armin P.
    Retterstol, Kjetil
    Kringen, Marianne K.
    MOLECULAR DIAGNOSIS & THERAPY, 2013, 17 (04) : 233 - 237
  • [43] Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:: roles of UGT1A1*6 and*28
    Minami, Hironobu
    Sai, Kimie
    Saeki, Mayumi
    Saito, Yoshiro
    Ozawa, Shogo
    Suzuki, Kazuhiro
    Kaniwa, Nahoko
    Sawada, Jun-ichi
    Hamaguchi, Tetsuya
    Yamamoto, Noboru
    Shirao, Kuniaki
    Yamada, Yasuhide
    Ohmatsu, Hironobu
    Kubota, Kaoru
    Yoshida, Teruhiko
    Ohtsu, Atsushi
    Saijo, Nagahiro
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 497 - 504
  • [44] Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 (FFCD 0504 trial): Final results
    Mitry, E.
    Bouche, O.
    Seitz, J.
    Etienne, P.
    Legoux, J.
    Aparicio, T.
    Breysacher, G.
    Lecaille, C.
    Lecomte, T.
    Jouve, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism
    Gil, Justyna
    Sasiadek, Maria M.
    BIOMARKERS IN MEDICINE, 2012, 6 (02) : 223 - 230
  • [46] Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project
    Hikino, Keiko
    Ozeki, Takeshi
    Koido, Masaru
    Terao, Chikashi
    Kamatani, Yoichiro
    Murakami, Yoshinori
    Kubo, Michiaki
    Mushiroda, Taisei
    JOURNAL OF HUMAN GENETICS, 2019, 64 (12) : 1195 - 1202
  • [47] Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome
    Bernabeu, Ignacio
    Marazuela, Monica
    Lucas, Tomas
    Loidi, Lourdes
    Alvarez-Escola, Cristina
    Luque-Ramirez, Manuel
    Fernandez-Rodriguez, Eva
    Paniagua, Amalia-Elisa
    Quinteiro, Celsa
    Casanueva, Felipe F.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05): : 2147 - 2154
  • [48] Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics
    Trontelj, Jurij
    Marc, Janja
    Zavratnik, Andrej
    Bogataj, Marija
    Mrhar, Ales
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (04) : 437 - 444
  • [49] Association of gallstone and polymorphisms of UGT1A1*27 and UGT1A1*28 in patients with hepatitis B virus-related liver failure
    Zhuo, Haiyan
    Fan, Jinhai
    Zhang, Bifeng
    Shi, Yixian
    Zheng, Liqing
    Chai, Yihong
    Yao, Lvfeng
    OPEN MEDICINE, 2022, 17 (01): : 1455 - 1465